Without a doubt, the brightest star in the summer night sky is Arcturus. It’s the second-brightest star in our night skies throughout the year. Only Sirius, the brightest star in the constellation ...

CEO and President Joe Payne outlined the company’s current focus on messenger RNA (mRNA) therapeutics, emphasizing a leaner ...

In late 2025, Arcturus Therapeutics Holdings Inc. filed an omnibus shelf registration of up to US$500 million, covering ...

Arcturus Therapeutics Holdings (ARCT) is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, ...

Investors might want to bet on Arcturus Therapeutics (ARCT), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Arcturus has developed the first sa-mRNA COVID-19 vaccine, Kostaive, in the world. The company has a collaboration agreement with renowned vaccine company CSL Seqirus for making innovative mRNA ...

Good day, everyone, and welcome to today's Arcturus Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the ...

Payne indicated that the company intends to "evaluate daily dosing of ARCT-032 over a 12-week duration in up to 20 CF participants," with this study planned to begin in the first half of 2026. He ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease ...

Looking at this spot in the sky, you can have your ice cream and eat it, too. Credit: Creators.com illustrationLooking at this spot in the sky, you can have your ice cream and eat it, too. One of my ...